WO2011077444A1 - A new process for the preparation of pure telmisartan - Google Patents

A new process for the preparation of pure telmisartan Download PDF

Info

Publication number
WO2011077444A1
WO2011077444A1 PCT/IN2010/000357 IN2010000357W WO2011077444A1 WO 2011077444 A1 WO2011077444 A1 WO 2011077444A1 IN 2010000357 W IN2010000357 W IN 2010000357W WO 2011077444 A1 WO2011077444 A1 WO 2011077444A1
Authority
WO
WIPO (PCT)
Prior art keywords
telmisartan
solvent
methyl
pure
base
Prior art date
Application number
PCT/IN2010/000357
Other languages
French (fr)
Inventor
Purna Chandra Ray
Satish Nigam
Anand Kumar Pandey
Premchand Patil
Jagan Mohan Reddy
Nagaraju Oruganti
Original Assignee
Inogent Laboratories Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IN3154CH2009 priority Critical
Priority to IN3154/CHE/2009 priority
Application filed by Inogent Laboratories Private Limited filed Critical Inogent Laboratories Private Limited
Publication of WO2011077444A1 publication Critical patent/WO2011077444A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical

Abstract

This invention provides a process for preparing pure telmisartan by condensing 2- n-propyl-4-methyl-6-(r-methylbenzimidazol-2'-yl) benzimidazole (I) with a compound of formula (II) to obtain the compound 2-cyano-4'-[2"-n-propyl-4"-methyl- 6"-(l"'-methylbenzimidazol-2"'-yl)benzimidazol-l"-ylmethyl] biphenyl (III), and subsequently hydrolyzing the isolated nitrile function group to obtain the telmisartan.

Description

A NEW PROCESS FOR THE PREPARATION OF PURE TELMISARTAN

Field of the Invention

The present invention relates to a new process for preparing 4'-[2-n-propyl-4- methyl-6-( 1 -methylbenzimidazol-2-yl)benzimidazol- 1 -ylmethyl]biphenyl-2- carboxylic acid (INN: telmisartan). More particularly, process for preparing pure 4'- [2-n-propyl-4-methyl-6-( 1 -methylbenzimidazol-2-yl)benzimidazol- 1 - ylmethyl]biphenyl-2-carboxylic acid (INN: telmisartan).

Background of the Invention

Telmisartan (brand name- Micardis) exhibits antihypertensive activity is an angiotensin II receptor antagonist used in the management of hypertension, heart . strokes and bladder diseases as described in EP 502314 Bl . It is chemical known as 4'-((l,7,-dimethyl-2,-propyl-lH,3,H-2,5,-bibenzo[d]imidazol-3'- yl)methyl)biphenyl-2-carboxylic acid with following structure:

Figure imgf000002_0001

1 Telmisartan 2 Impurity B

Various process for the preparation of telmisartan has been reported in the prior art. The patent EP 502314 Bl describe the preparation of telmisartan by condensation of -n-propyl-4-methyl-6-(r-methylbenzimidazol-2'-yl)benzimidazole with alkyl 4'- (bromomethyl) biphenyl-2-carboxylate and subsequent hydrolysis yield the title product. The main limitation of the process is the formation of several impurities more particularly is the impurity B (I) as per European Pharmacopeia which results to poor yield. US 7193089 B2 discloses the preparation of telmisartan by reacting 2-n-propyl-4- methyl-6-( 1 '-methylbenzimidazol-2'-yl)benzimidazole with 4'-Bromomethyl-2- cyanobiphenyl to obtain 2-cyano-4'-[2"-n-propyl-4"-methyl-6"- (Γ"- methylbenzimidazol-2"'-yl) benzimidazole -l"-ylmethyl] biphenyl, subsequent hydrolyzing the nitrile function of compound obtained from step (a) into the acid function to obtain telmisartan. This process involves use of tert-butylmethylether for isolation of telmisartan nitrile, high temperature distillation and workups at 80°C in the preparation of telmisartan hydrochloride which is very unsafe; and product obtained results of poor yield.

WO 2006103068 Al (examples 10 & 1 1) covers the process for preparation of telmisartan where use of chemicals like DIBAL-H, sodium perborate and Kmno4 is not convenient to handle for large scale production because of the corrosive problems and environmental problems associated by using them, and very low yield of the product is reported.

US 20060264491 Al (example 1 & 2) discloses a process for the preparation of telmisartan by reacting 4'-[(l,4'-dimethyl-2'-propyl [2,6'-bi-lH-benzimidazol]-l'- yl)methyl]-[l,l'- biphenyl] -2-carboxamide with potassium hydroxide powder, and propylene glycol. This process involves high temperature distillation and work up and also the product obtained by this method doesn't meet the requirements of European pharmacopoeia.

All the reported process does not describe, how to control impurity B, which is the regioismer generate during condensation step, to the desired pharmacopeial limit <0.15% either at condensation or at hydrolysis step. We found that all the processes suffer with the formation of impurity 2 (Table-1). So in order to meet the desired quality requirement, it always needs exhaustive purification operations. This resulted more processing time, huge waste generation, poor productivity, less yield and finally high cost. Therefore this is always required for efficient cost effective process of telmisartan which meets pharmacopoeia and ICH quality requirements. Table 1 : Preparation of Telmisartan and 2 with reported synthetic schemes

Figure imgf000004_0001

*HPLC reaction monitoring data, ** Isolated yield for hydrolysis step of pure product The aim of the present invention is therefore to provide an alternative method of preparing telmisartan, which can be used on a large scale and allows telmisartan to be easily worked up, purified, and isolated without the disadvantages mentioned above.

Object and Summary of the Invention

It is a principal object of the present invention to provide a process for the production of telmisartan.

It is a further object of the present invention to provide a pure process for producing telmisartan.

It is another object of the present invention to provide a process for producing telmisartan by condensation of N-methyl dibenzimidazole with 4'-Bromomethyl-2- cyanobiphenyl to obtain telmisartan nitrile.

It is yet another object of the present invention to provide a process for producing telmisartan, wherein the process requires low boiling distillation, as well as minimized isolation procedure in. This provides for better control for the process related impurities also.

According to the first aspect, the present invention provides a process for the preparation of telmisartan, comprising: condensation of -n-propyl-4-methyl-6-(l'- methylbenzimidazol-2'-yl)benzimidazole (I)

Figure imgf000005_0001

with a compound of general formula II)

Figure imgf000005_0002
wherein Z denotes a leaving group such as a halogen atom, for example, a chlorine, bromine, or iodine atom to obtain the compound 2-cyano-4'-[2"-n-propyl-4"-methyl- 6"-( 1 "'-methylbenzimidazol-2"'-yl)benzimidazol- 1 "-ylmethyl]biphenyl (III), and subsequent

Figure imgf000005_0003

hydrolysis of nitrile in the presence of excess base and solvent followed by acid/base purification to obtain pure telmisartan.

Figure imgf000005_0004

Detailed description of the Invention

While this specification concludes with claims particularly pointing out and distinctly claiming that, which is regarded as the invention, it is anticipated that the invention can be more readily understood through reading the following detailed description of the invention and study of the included examples.

According to the present invention, condensation of -n-propyl-4-methyl-6-(l'- methylbenzimidazol-2'-yl)benzimidazole (I) with a compound of general formula (II) in wherein Z preferably denotes a halogen atom, particularly the bromine atom, is conveniently carried out in a ketonic solvent such as acetone, MIBK (methyl isobutyl ketone, ethyl isopropyl ketone, methyl isopropyl ketone, methylethyl ketone, terbutyl methyl ketone, in the presence of base such as sodium hydroxide or potassium hydroxide at a temperature between 10[deg.] C. and 40[deg.] C.

Preferably, the reaction of the compound (I) with a compound of general formula

(II) in wherein Z preferably denotes a halogen atom, particularly the bromine atom, is conveniently carried out in a ketonic solvent such as acetone, MIBK (methyl isobutyl ketone, ethyl isopropyl ketone, methyl isopropyl ketone, methylethyl ketone, terbutyl methyl ketone, in the presence of base such as potassium hydroxide at a temperature between 15[deg.] C. and 30[deg.] C. 1

Particularly preferably, the condensation of the compound (I) with a compound of general formula (II) in wherein Z preferably denotes a halogen atom, particularly the bromine atom, is conveniently carried out in a ketonic solvent such as acetone in the presence of base such as potassium hydroxide at a temperature between 20 [deg.] C. and 25 [deg.] C. to obtain compound 2-cyano-4'-[2"-n-propyl-4"-methyl-6"-(r"- methylbenzimidazol-2"'-yl)benzimidazol-l"-ylmethyl]biphenyl (III). After the completion of the reaction the material is filtered, washed with chilled acetone, followed by washings with water, and then dried in a air dryer to get the telmisartan Nitrile.

Hydrolysis of the isolated compound (III) in excess amount of base in the presence of solvent to obtain telmisartan at a temperature ranging from 120 [deg.] C. and 180 [deg.] C.

Preferably, hydrolysis of the compound (III) is carried out in the presence of excess base such as sodium hydroxide or potassium hydroxide in the presence of solvents such as ethylene glycol, DMSO, DMF, Dimethyl acetamide at a temperature ranging from 140 [deg.] C. and 170 [deg.] C. More preferably, hydrolysis of the compound (III) is carried out in the presence of excess base such as potassium hydroxide in the presence of solvents such as ethylene glycol, at a temperature ranging from from 150 [deg.] C. and 160 [deg.] C. The reaction is show below in Scheme I.

Scheme-I

Figure imgf000007_0001
Figure imgf000007_0002

After the completion of the reaction the reaction mass is cooled to 20-25 [deg.] C. and dilute by adding alcohols such as methanol, ethanol and butanol, more preferably methanol, precipitate the material with acid such as acetic acid by adjusting the pH 5.7 - 6.0 at 20-25 [deg.] C and dilute further by adding de-mineralized water. Stir the precipitate for 60 mns in the same temperature, and then the crystals are suction filtered. The wet material dissolve in alcohol such as methanol, ethanol and butanol, more preferably methanol with non aqueous organic base or inorganic base such as triethyl amine, diisoprolyl ethyl amine, potassium hydroxide or sodium hydroxide preferably potassium hydroxide, followed by treatment of charcoal crystallize the telmisartan by adding acetic acid. Isolation with filtration and washing with water, then dried in a tray drier to obtain pure telmisartan.

Alternatively, invention also describes the single pot process for preparation of telmisartan without isolating 2-cyano-4'-[2"-n-propyl-4"-methyl-6"-( "- methylbenzimidazol-2'"-yl)benzimidazol-l"-ylmethyl]biphenyl (III) and subsequently hydrolyzing to form telmisartan.

The invention is further explained in detail in the following examples which is provided by way of illustrations only and should not be construed to limit the scope of the invention.

EXAMPLES:

Experiment-1: Preparation of 2-cyano-4-[2-n-propyl-4-methyI-6-(l- methylbenzimidazol-2-yl) bnzimidazol-l-ylmethyl] biphenyl.

Add 2-n-propyl-4-methyl-6-(l '-methylbenzimidazol-2'-yl) benzimidazole 100 g in 1000ml of acetone and of potassium hydroxide 22.0 g with stirring at 20-25°C. Then of 4-bromomethyl-2'-cyanobiphenyl 92g is added at 20-25°C. Monitor the reaction on thin layer chromatography, after compilation reaction, the crystals are suction filtered, washed with chilled acetone, water, and then dried in a air drying cupboard at 80° C. Yield: 135.0 g (82.82% of theory); melting point: 196° C.-197° C; HPLC: 99.30%. N-3 isomer: 0.08%.

Experiment-2: Preparation of 2-cyano-4-[2-n-propyl-4-methyl-6-(l- methylbenzimidazol-2-yl) benzimidazol-l-ylmethyl] biphenyl.

Add 2-n-propyl-4-methyl-6-( -methylbenzimidazol-2'-yl) benzimidazole 100 g in 1000ml of acetone and of potassium hydroxide 22.0 g with stirring at 20-25°C. Then of 4-bromomethyl-2'-cyanobiphenyl 92g is added at 20-25 °C. Monitor the reaction on thin layer chromatography, after the reaction is completed, cooled to 0 to 5.0° C. and stirred for another hour at this temperature. The material is filtered, washed with chilled acetone, then wash with water, and then dried in a air drying cupboard at 80° C. Yield: 141.50 g (87.73% of theory); melting point: 196° C.-197° C; HPLC: 99.50%. N-3 isomer: 0.16%

Experiment-3: Preparation of Telmisartan.

Add potassium hydroxide 80g in 500ml of ethylene glycol then add 2-cyano-4'- [2-n-propyl-4-methyl-6-( 1 -methyl benzimidazol-2-yl) benzimidazol- 1 -ylmethyl] biphenyl lOOgm at room temperature. Stir the reaction mixture and raise temperature to 150- 155° C. The mixture is stirred for 15 to 18 hours at this temperature and monitor reaction mass by HPLC. After compilation of reaction cool to 30 to 35°C then diluted with 800 ml methanol then telmisartan precipitates by adding of acetic acid at 25 to 30°C and further diluted with water. Then stirred for further 90min at 25 to 30°C. After the crystals have been suction filtered. The wet material dissolve in 500ml methanol with 12gm potassium hydroxide then after treatment of charcoal crystallize the telmisartan to adjusting of pH 6.0 to 6.4 by acetic acid then dilute with 400ml water. Filtered and then dried in a vacuum tray drier at 85°C. Yield: 90g (87.37% of theory); HPLC: 99.91%.

Experiment-4: Preparation of Telmisartan.

Add potassium hydroxide lOOg in 500ml of ethylene glycol then add 2-cyano- 4'-[2-n-propyl-4-methyl-6-(l -methyl benzimidazol-2-yl) benzimidazol- 1 -ylmethyl] biphenyl 1 OOgm at room temperature. Stir the reaction mixture and raise temperature to 150-155° C. The mixture is stirred for 15 to 18 hours at this temperature and monitor reaction mass by HPLC. After compilation of reaction cool to 30 to 35°C then diluted with 800ml methanol then telmisartan crystallize by adding of acetic acid at 25 to 30°C then dilute with 300ml water. Stir for further 90min at 25 to 30°C. Filter and then dried in a vacuum drying cupboard at 85°C. Yield: 101 g (1.03% of theory); HPLC: 99.90%.

Experiment-5: Preparation of pure Telmisartan.

Crude telmisartan 101 g (from example 4) & activated carbon lOg is added in methanol 100ml , dichloromethane 500ml at 25 to 30°C. Stir the reaction mixture then the brown solution is filtered through hyflow bed, Completely distilled out filtrate below 50°C then add 800ml water at that temperature and stir for lhr. The telmisartan is hot filtered and washed with water. The telmisartan is dried at 80° C. in a vacuum drying cupboard. Yield: 90 g (87.37% of theory); HPLC: >99.95%.

Experiment-6: Preparation of Telmisartan.

2-cyano-4'- [2-n-propyl-4-methyl-6-( 1 -methyl benzimidazol-2-yl) benzimidazol- 1 - ylmethyl] biphenyl lOOgm is added in 500ml of ethylene glycol with lOOg of potassium hydroxide powder at 20-25°C. Stir and raise temperature to 160° C. to 165° C. The mixture is stirred for 15 to 18 hours at this temperature and monitor reaction mass by HPLC. After compilation of reaction cool to 70 to 75°C then diluted with methanol and water then telmisartan crystallize by adding of acetic acid to adjust the pH 5.5 to 6.0 at 25 to 30°C. Stir for further 60min at 25 to 30°C. After the crystals have been suction filtered. The wet material dissolve in methanol with potassium hydroxide 12gm then after treatment of charcoal crystallize the telmisartan by adding of acetic acid by adjusting of pH 6.0 to 6.4 then stir for further 60min. The material is filtered and dried in a vacuum drying cupboard at 85°C. Yield: 86.56g (84.03% of theory); HPLC: >99.96%.

Experiment-7: Preparation of Telmisartan.

of 2-n-propyl-4-methyl-6-(r-methylbenzimidazol-2'-yl) benzimidazole 100 g is add in 1000 ml of acetone, and of potassium hydroxide 22 gm with stirring at 20-25° C and then 90.0 g of 4-bromomethyl-2'-cyanobiphenyl is added at 20-25°C. The temperature of the reaction mixture is maintained at 20 to 25° C. Stir for a further 6.0 to 8.0 hours at 20 to 25° C. Monitor the reaction on thin layer chromatography, after compilation reaction distil out acetone. Add ethylene glycol 500ml and potassium hydroxide lOOgm to residue Stir the reaction mixture and raise temperature to 150° C. to 155° C. The mixture is stirred for 15 to 18 hours at this temperature and monitor reaction mass by HPLC. After compilation of reaction cool to 30 to 35°C. Reaction mass diluted with methanol and stir for 30min then telmisartan precipitated by adding of acetic acid to adjust the pH 6.0 to 6.5 at 25 to 30°C. Then dilute with water and filter, wash with of methanol. Wet telmisartan is dissolved in methanolic potassium hydroxide, filtered to remove un dissolved material. Acetic acid is added to adjust the pH 6.0 to 6.4 , water added for complete precipitation of material. Finally telmisartan is suction filter and wash with water at 40 to 45 °C. The telmisartan is dried at 80° C. in a vacuum drying cupboard. Yield: 130g HPLC: 99.4%.1H NMR (DMSO-d6) δ 1.0 (t,3H), 1.9 (q, 2H), 2.95 (t, 2H), 2.4 (s, 3H), 3.95 (s, 3H), 5.8 (s, 2H), 7.28 (s,lH),7.80 (s,lH), 7.75 (d, 2H), 7.25 (t, 2H), 7.10 (d, 2H), 7.30 (d, 2H), 7.40 (d, 1H), 7.40 (t, 1H), 7.30 (t, 1H), 7.45 (d, 1H). 12.9 (s, 1H). m/z 514.7 [ M + H]+.

Claims

We Claim:
1. A process for the preparation of pure telmisartan with Impurity B <0.05%, without the isolation of telmisartan salts comprising:
a. Condensation of -n-propyl-4-methyl-6-( -methylbenzimidazol-2'- yl)benzimidazole (I) with a compound of general formula (II) conveniently carried out in a ketonic solvent in the presence of base to obtain telmisartan nitrile (III) and followed by isolation.
Figure imgf000011_0001
b. Hydrolysis of isolated compound (III) by using base at a temperature between 120[deg.] C. and 180[deg.] C in second solvent to obtain telmisartan.
c. After completion of hydrolysis third solvent is added and pH adjusted in neutral range to obtain telmisartan.
d. Product is filtered, followed by washing with water.
e. Wet material is further dissolved in third solvent in the presence of base and filtered to get clear solution.
f. Added acid to crystallize the telmisartan.
g. Filter, wash with water and dry to get the pure telmisartan
2. The process according to claim 1, wherein the ketonic solvents is selected from the group acetone, methyl isobutyl ketone, ethyl isopropyl ketone, methyl isopropyl ketone, methylethyl ketone and terbutyl methyl ketone.
3. The process according to claim 2, wherein the said ketonic solvents is acetone.
4. The process according to claim 1, wherein the said base is selected from sodium hydroxide, potassium hydroxide and lithium hydroxide.
5. The process according to claim 4, wherein the said base selected is potassium hydroxide.
6. The process according to claim 1, wherein isolation of telmisartan nitrile (III) is carried out by filtration.
7. The process according to claim 1, wherein the said second solvent is selected from the group ethylene glycol, DMSO, DMF and dimethyl acetamide.
8. The process according to claim 7, wherein the said second solvent selected is ethylene glycol.
9. The process according to claim 1, wherein the said third solvent is selected from the group of alcohols.
10. The process according to claim 9, wherein the said third solvent selected is methanol, ethanol, propanol, butanol, ethylene glycol and monoglyme.
1 1. The process according to claim 10, wherein wherein the said third solvent selected is methanol.
12. The process according to claim 1, wherein pure telmisartan is obtained with purity not less than 99.5% and impurity B <0.15%
13. The process according to claim 1, wherein pure telmisartan is obtained with purity not less than 99.8% and impurity B <0.10%
14. The process according to claim 1, wherein pure telmisartan is obtained with purity not less than 99.9% and impurity B <0.05%
15. Telmisartan is prepared by procedures described above without isolating telmisartan nitrile and subsequent hydrolysis to obtain pure telmisartan.
PCT/IN2010/000357 2009-12-22 2010-05-28 A new process for the preparation of pure telmisartan WO2011077444A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IN3154CH2009 2009-12-22
IN3154/CHE/2009 2009-12-22

Publications (1)

Publication Number Publication Date
WO2011077444A1 true WO2011077444A1 (en) 2011-06-30

Family

ID=44195034

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2010/000357 WO2011077444A1 (en) 2009-12-22 2010-05-28 A new process for the preparation of pure telmisartan

Country Status (1)

Country Link
WO (1) WO2011077444A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014067237A1 (en) * 2012-10-31 2014-05-08 上海特化医药科技有限公司 Telmisartan preparation method and intermediate thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060264491A1 (en) * 2006-06-08 2006-11-23 Chemagis Ltd. Telmisartan production process

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060264491A1 (en) * 2006-06-08 2006-11-23 Chemagis Ltd. Telmisartan production process

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REDDY ET AL.: "An Efficient and Impurity-Free Process for Telmisartan: An Antihypertensive Drug.", ORGANIC PROCESS IN RESEARCH AND DEVELOPMENT, vol. 11, 2007, pages 81 - 85, XP002505650, DOI: doi:10.1021/OP060200G *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014067237A1 (en) * 2012-10-31 2014-05-08 上海特化医药科技有限公司 Telmisartan preparation method and intermediate thereof
CN103787982A (en) * 2012-10-31 2014-05-14 上海特化医药科技有限公司 Telmisartan preparation method and intermediate of telmisartan
CN104768936A (en) * 2012-10-31 2015-07-08 上海特化医药科技有限公司 Enzalutamide polymorphic forms and its preparation
CN104768936B (en) * 2012-10-31 2017-07-28 上海特化医药科技有限公司 Prepare the method and its intermediate of Telmisartan

Similar Documents

Publication Publication Date Title
US8420829B2 (en) Processes for the preparation of bendamustine
ES2610434T3 (en) Crystalline minocycline base and preparation procedures
JP5269798B2 (en) Trityl olmesartan medoxomil and method for producing olmesartan medoxomil
EP2673274B1 (en) An improved process for the preparation of azilsartan medoxomil
US8884033B2 (en) Process for preparing aminobenzoylbenzofuran derivatives
ES2208265T3 (en) Telmisartan polymorphes, procedure for preparation and use for the preparation of a medicinal product.
JP5735465B2 (en) Process for producing 5- (4- [4- (5-cyano-3-indolyl) butyl] -1-piperazinyl) benzofuran-2-carboxamide
US8592474B2 (en) Process for the preparation or purification of olmesartan medoxomil
CA2141175C (en) A process for the production of tetrazolyl compounds
US8993778B2 (en) Process for manufacture of telmisartan
ES2308494T3 (en) Process for the preparation of telmisartan.
US9657029B2 (en) Method of preparing oxymorphone
US7943781B2 (en) Process for preparing telmisartan
CA2808230A1 (en) Process for producing 1-triazole-2-butanol derivatives
JP6307087B2 (en) Compounds useful for the synthesis of benzamide compounds
US20100197915A1 (en) Lapatinib intermediates
EP2885266B1 (en) Process for the preparation of (2z,5z)-5-(3-chloro-4-((r)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one and intermediate used in said process
EP2024343B1 (en) Process for purification of anastrozole
CZ305085B6 (en) Process for preparing dabigatran
JP2008508258A5 (en)
ES2274473T3 (en) Improved procedure to prepare eletriptan alfa-polymorph hydrobromide.
EP2681201B1 (en) A method of manufacturing 2-ethoxy-1-(2&#39;-((hydroxyamino)iminomethyl)biphenyl-4-yl) methyl)-1h-benzo(d)imidazole-7-carboxylic acid and its esters
CZ307500B6 (en) A method of the preparation of a 2-methyl-2&#39;-phenylpropionic acid derivative employing novel intermediates
US20150175554A1 (en) Highly pure bendamustine hydrochloride monohydrate
JP5203703B2 (en) Method for producing irbesartan and its intermediate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10838829

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10838829

Country of ref document: EP

Kind code of ref document: A1